JP2021533777A5 - - Google Patents
Info
- Publication number
- JP2021533777A5 JP2021533777A5 JP2021507743A JP2021507743A JP2021533777A5 JP 2021533777 A5 JP2021533777 A5 JP 2021533777A5 JP 2021507743 A JP2021507743 A JP 2021507743A JP 2021507743 A JP2021507743 A JP 2021507743A JP 2021533777 A5 JP2021533777 A5 JP 2021533777A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- seq
- amino acid
- nucleic acid
- recombinant nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024035703A JP2024060024A (ja) | 2018-08-16 | 2024-03-08 | Ｔ細胞受容体構築物およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862764817P | 2018-08-16 | 2018-08-16 | |
| US62/764,817 | 2018-08-16 | ||
| US201962810112P | 2019-02-25 | 2019-02-25 | |
| US62/810,112 | 2019-02-25 | ||
| PCT/US2019/046876 WO2020037239A1 (en) | 2018-08-16 | 2019-08-16 | T cell receptor constructs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024035703A Division JP2024060024A (ja) | 2018-08-16 | 2024-03-08 | Ｔ細胞受容体構築物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021533777A JP2021533777A (ja) | 2021-12-09 |
| JP2021533777A5 true JP2021533777A5 (https=) | 2022-08-29 |
Family
ID=69525945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507743A Pending JP2021533777A (ja) | 2018-08-16 | 2019-08-16 | Ｔ細胞受容体構築物およびその使用 |
| JP2024035703A Pending JP2024060024A (ja) | 2018-08-16 | 2024-03-08 | Ｔ細胞受容体構築物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024035703A Pending JP2024060024A (ja) | 2018-08-16 | 2024-03-08 | Ｔ細胞受容体構築物およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12331097B2 (https=) |
| EP (1) | EP3837279A4 (https=) |
| JP (2) | JP2021533777A (https=) |
| KR (1) | KR20210074277A (https=) |
| CN (2) | CN112888707B (https=) |
| AU (2) | AU2019321608B2 (https=) |
| BR (1) | BR112021002826A2 (https=) |
| CA (1) | CA3109232A1 (https=) |
| IL (1) | IL280718B2 (https=) |
| MX (1) | MX2021001837A (https=) |
| PH (1) | PH12021550307A1 (https=) |
| SG (1) | SG11202101524RA (https=) |
| TW (1) | TW202021982A (https=) |
| WO (1) | WO2020037239A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2670848B1 (en) | 2011-02-06 | 2016-02-03 | Yeda Research and Development Co. Ltd | Affinity maturated t cell receptors and use thereof |
| CN112584852A (zh) * | 2018-06-19 | 2021-03-30 | 百欧恩泰美国公司 | 新抗原及其用途 |
| JP2021533777A (ja) | 2018-08-16 | 2021-12-09 | ビオンテック ユーエス インコーポレイテッド | Ｔ細胞受容体構築物およびその使用 |
| WO2020154617A1 (en) * | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| CN114026116A (zh) * | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| US20230241205A1 (en) * | 2020-06-17 | 2023-08-03 | Tscan Therapeutics, Inc. | Sars-cov-2 immunodominant peptides and uses thereof |
| IL276599A (en) * | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
| WO2022036103A1 (en) * | 2020-08-13 | 2022-02-17 | Rootpath Genomics, Inc. | Compositions and methods for antigen identification |
| TW202229327A (zh) * | 2020-10-02 | 2022-08-01 | 美國衛生與公眾服務部 | 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US20240000834A1 (en) * | 2020-11-24 | 2024-01-04 | Shanghai GenBase Biotechnology Co., Ltd. | Ras mutant epitope peptide and t cell receptor recognizing ras mutant |
| BR112023014628A2 (pt) * | 2021-01-21 | 2023-10-03 | Univ Erasmus Med Ct Rotterdam | Células t para uso em terapia. |
| WO2022216574A1 (en) * | 2021-04-05 | 2022-10-13 | Janssen Biotech, Inc. | Calr and jak2 t-cell receptors |
| AU2022256469A1 (en) * | 2021-04-14 | 2023-10-12 | Academisch Ziekenhuis Leiden | Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof |
| US20240190940A1 (en) * | 2021-04-21 | 2024-06-13 | The United States of America, as represented by the Secretary, Department of Health and Human Serice | Hla class i-restricted t cell receptors against ras with q61k mutation |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| WO2022235577A2 (en) * | 2021-05-03 | 2022-11-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1 |
| JP2024540197A (ja) * | 2021-10-29 | 2024-10-31 | ホウ，ヤフェイ | Ｐ５３におけるｒ１７５ｈ変異を認識するｔ細胞受容体およびその用途 |
| AU2023269157A1 (en) * | 2022-05-13 | 2024-11-07 | Fred Hutchinson Cancer Center | Binding proteins specific for ras neoantigens and uses thereof |
| TW202402798A (zh) * | 2022-05-23 | 2024-01-16 | 美商艾費尼Ｔ醫療公司 | 對新抗原具特異性之結合蛋白與工程化細胞及其用途 |
| CN117264043B (zh) * | 2022-06-14 | 2024-05-10 | 上海镔铁生物科技有限责任公司 | 靶向kras g12v突变多肽的t细胞受体及其用途 |
| WO2024039576A2 (en) * | 2022-08-19 | 2024-02-22 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| WO2024148185A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*11:01 in lung cancer |
| WO2024148183A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*03:01 in lung cancer |
| WO2024148181A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*11:01 in lung cancer |
| WO2024148178A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer |
| KR20250143879A (ko) * | 2023-01-13 | 2025-10-02 | 코레진 바이오테크놀로지 컴퍼니 리미티드 | 항원 결합 단백질 및 그 용도 |
| CN121127257A (zh) * | 2023-02-03 | 2025-12-12 | Affini-T治疗有限公司 | 携带kras结合蛋白并敲除内源性tcr的宿主细胞及其使用方法 |
| IL304887A (en) * | 2023-07-31 | 2025-02-01 | Yeda Res & Dev | T-cell receptor directed against RAS neoantigen |
| WO2025179050A2 (en) * | 2024-02-21 | 2025-08-28 | Biontech Us Inc. | Vaccine compositions and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| WO1994003205A1 (en) | 1992-08-07 | 1994-02-17 | Cytel Corporation | Hla binding peptides and their uses |
| BR9406652A (pt) | 1993-03-05 | 1996-09-10 | Cytel Corp | Composição |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| IL160359A0 (en) | 2001-08-31 | 2004-07-25 | Avidex Ltd | Soluble t cell receptor |
| CA2501870C (en) | 2002-10-09 | 2013-07-02 | Avidex Limited | Single chain recombinant t cell receptors |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| EP2486049A1 (en) | 2009-10-06 | 2012-08-15 | The Board Of Trustees Of The UniversityOf Illinois | Human single-chain t cell receptors |
| US20150104441A1 (en) | 2013-10-11 | 2015-04-16 | Oslo Universitetssykehus Hf | Identification of disease-driving antigens |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| CN118994363A (zh) * | 2014-11-26 | 2024-11-22 | 美国卫生和人力服务部 | 抗突变的kras的t细胞受体 |
| WO2016154246A1 (en) * | 2015-03-23 | 2016-09-29 | The Johns Hopkins University | Hla-restricted epitopes encoded by somatically mutated genes |
| US20190119350A1 (en) | 2015-09-09 | 2019-04-25 | Immune Design Corp. | Ny-eso-1 specific tcrs and methods of use thereof |
| ES2879287T3 (es) * | 2015-09-15 | 2021-11-22 | Us Health | Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8 |
| JP2019513373A (ja) | 2016-03-31 | 2019-05-30 | ネオン セラピューティクス， インコーポレイテッド | ネオ抗原およびその使用方法 |
| CN108395479B (zh) | 2017-02-06 | 2021-07-16 | 高军 | 一种有关kras基因突变的t细胞受体 |
| JP2021533777A (ja) | 2018-08-16 | 2021-12-09 | ビオンテック ユーエス インコーポレイテッド | Ｔ細胞受容体構築物およびその使用 |
-
2019
- 2019-08-16 JP JP2021507743A patent/JP2021533777A/ja active Pending
- 2019-08-16 IL IL280718A patent/IL280718B2/en unknown
- 2019-08-16 AU AU2019321608A patent/AU2019321608B2/en active Active
- 2019-08-16 TW TW108129290A patent/TW202021982A/zh unknown
- 2019-08-16 CN CN201980068674.6A patent/CN112888707B/zh active Active
- 2019-08-16 BR BR112021002826-9A patent/BR112021002826A2/pt unknown
- 2019-08-16 US US17/268,915 patent/US12331097B2/en active Active
- 2019-08-16 SG SG11202101524RA patent/SG11202101524RA/en unknown
- 2019-08-16 CA CA3109232A patent/CA3109232A1/en active Pending
- 2019-08-16 CN CN202510427956.8A patent/CN120249298A/zh active Pending
- 2019-08-16 EP EP19849341.3A patent/EP3837279A4/en active Pending
- 2019-08-16 WO PCT/US2019/046876 patent/WO2020037239A1/en not_active Ceased
- 2019-08-16 MX MX2021001837A patent/MX2021001837A/es unknown
- 2019-08-16 KR KR1020217007749A patent/KR20210074277A/ko not_active Ceased
-
2021
- 2021-02-11 PH PH12021550307A patent/PH12021550307A1/en unknown
-
2024
- 2024-03-08 JP JP2024035703A patent/JP2024060024A/ja active Pending
- 2024-10-25 AU AU2024227645A patent/AU2024227645A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533777A5 (https=) | ||
| JP7803939B2 (ja) | Ｋｒａｓ変異に特異的ｔ細胞受容体のスクリーニング及び抗腫瘍用途 | |
| US12297252B2 (en) | T cell receptors with improved pairing | |
| KR102809909B1 (ko) | P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법 | |
| Tran et al. | T-cell transfer therapy targeting mutant KRAS in cancer | |
| Yuan et al. | Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma | |
| IL268917B2 (en) | A population-based immunogenic peptide identification platform | |
| JP2019520591A5 (https=) | ||
| JP2021535749A5 (https=) | ||
| AU2016264623A1 (en) | Shared neoantigens | |
| CN113906141B (zh) | T细胞受体及其使用方法 | |
| CN113795585B (zh) | T细胞受体及其使用方法 | |
| US20250333504A1 (en) | Treatment | |
| CN113785064B (zh) | T细胞受体及其使用方法 | |
| AU2022301201B2 (en) | A method for identifying variants in gene products from gene constructs used in cell therapy applications | |
| CA3229551A1 (en) | Vaccine design pipeline | |
| ES3048639T3 (en) | A modified hla-b57 with increased expression levels | |
| CN116574748B (zh) | 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法 | |
| WO2024215872A1 (en) | Human t cell receptors targeting tumor-enhanced splicing epitopes on hla-a*02:01 for small cell carcinoma | |
| CA3239837A1 (en) | Treatment | |
| HK40089777A (en) | Screening and antitumor use of kras mutation specific t cell receptor |